Swedish AI Precision Pathology (SwAIPP): Routes to clinical implementation of AI precision pathology (2.5 years)
| Reference number | |
| Coordinator | Karolinska Institutet - Karolinska Institutet Inst f medicinsk epidemiologi & |
| Funding from Vinnova | SEK 19 999 496 |
| Project duration | October 2021 - December 2024 |
| Status | Completed |
| Venture | SWElife, strategic project |
| Call | Innovation milleus in precision health 2021 |
Important results from the project
SwAIPP has strengthened the capacity to develop and implement AI-based precision diagnostics in Sweden. Stratipath Breast was launched for breast cancer risk stratification and has CE-IVDD-mark and IT integration with digital pathology systems. Two healthcare regions have implemented the solution, and several validation studies have been conducted. SwAIPP has actively worked on compliance issues and quality systems. Communication has taken place via publications, seminars and social media.
Expected long term effects
Clinical implementation of AI diagnostics is challenging, but SwAIPP has, with VINNOVA´s support, accelerated the development and clinical introduction of Stratipath Breast. This strengthens Swedish and European capacity for AI solutions, enabling precision diagnostics for all breast cancer patients and reducing both over- and under-treatment. SwAIPP has contributed to further national and international collaborations that drive research, development and commercial implementation forward.
Approach and implementation
SwAIPP is a multi-sector collaboration between leading partners in academia, healthcare, industry and patient organizations, with an objective to contribute to the development, clinical translation and adoption of AI-based precision diagnostics. Most milestones have been achieved according to the schedule, which included the launch of a regulatory approved product, the conduct of validation studies, and clinical implementation.